Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Arbovirus Infections

ClinicalTrials.gov lists 593 trials for Arbovirus Infections or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 58.

MeSH D001102 Infections C01
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 116 Phase 1/2 Phase 1/2 14 Phase 2 Phase 2 104 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 86 Phase 4 Phase 4 38 Not applicable Not applicable 75 Observational Observational 148 Phase 1 Phase 1 116 Phase 1/2 Phase 1/2 14 Phase 2 Phase 2 104 Phase 2/3 Phase 2/3 11 Phase 3 Phase 3 86 Phase 4 Phase 4 38 Not applicable Not applicable 75 Observational Observational 148

Trials per phase

1 more section with rows

21 of the 593 trials are tagged with Arbovirus Infections itself; the rest are tagged with a narrower condition beneath it.

Get the Arbovirus Infections report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Arbovirus Infections trials start? (27)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 49

1998: 1 trials (Phase 2/3 1) 2001: 3 trials (Phase 3 1, Phase 2 2) 2002: 6 trials (Phase 3 2, Phase 2 4) 2003: 2 trials (Phase 2 1, Phase 1/2 1) 2004: 8 trials (Phase 4 2, Phase 2 3, Phase 1/2 1, Phase 1 2) 2005: 23 trials (Observational 2, Phase 4 3, Phase 3 8, Phase 2 4, Phase 1/2 1, Phase 1 5) 2006: 16 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 4, Phase 2 4, Phase 1 4) 2007: 18 trials (Observational 4, Phase 4 4, Phase 3 2, Phase 2 5, Phase 1 3) 2008: 18 trials (Phase 4 2, Phase 3 4, Phase 2 8, Phase 1/2 2, Phase 1 2) 2009: 21 trials (Observational 2, Not applicable 1, Phase 4 2, Phase 3 3, Phase 2 9, Phase 1 4) 2010: 26 trials (Observational 5, Not applicable 2, Phase 4 1, Phase 3 9, Phase 2 2, Phase 1 7) 2011: 20 trials (Observational 5, Not applicable 1, Phase 3 7, Phase 2/3 1, Phase 2 1, Phase 1 5) 2012: 18 trials (Observational 4, Not applicable 1, Phase 4 5, Phase 3 1, Phase 2 2, Phase 1/2 1, Phase 1 4) 2013: 17 trials (Observational 3, Not applicable 1, Phase 4 3, Phase 3 1, Phase 2 3, Phase 1 6) 2014: 19 trials (Observational 5, Not applicable 3, Phase 3 1, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 4) 2015: 23 trials (Observational 5, Not applicable 1, Phase 4 5, Phase 3 2, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 4) 2016: 49 trials (Observational 21, Not applicable 6, Phase 4 1, Phase 3 5, Phase 2 5, Phase 1 11) 2017: 31 trials (Observational 9, Not applicable 6, Phase 4 1, Phase 3 3, Phase 2 5, Phase 1 7) 2018: 33 trials (Observational 9, Not applicable 6, Phase 4 1, Phase 3 2, Phase 2 6, Phase 1/2 1, Phase 1 8) 2019: 22 trials (Observational 3, Not applicable 3, Phase 4 2, Phase 3 2, Phase 2 4, Phase 1 8) 2020: 22 trials (Observational 7, Not applicable 5, Phase 3 1, Phase 1/2 2, Phase 1 7) 2021: 31 trials (Observational 7, Not applicable 7, Phase 4 1, Phase 3 5, Phase 2/3 2, Phase 2 6, Phase 1 3) 2022: 26 trials (Observational 7, Not applicable 5, Phase 3 4, Phase 2 4, Phase 1 6) 2023: 26 trials (Observational 9, Not applicable 7, Phase 3 3, Phase 2 5, Phase 1/2 1, Phase 1 1) 2024: 36 trials (Observational 14, Not applicable 6, Phase 4 3, Phase 3 3, Phase 2 4, Phase 1/2 1, Phase 1 5) 2025: 44 trials (Observational 17, Not applicable 6, Phase 4 1, Phase 3 7, Phase 2/3 2, Phase 2 5, Phase 1/2 1, Phase 1 5)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 29
2025 44
2024 36
2023 26
2022 26
2021 31
2020 22
2019 22
2018 33
2017 31

Showing 10 of 27 earlier years.

Start your 14-day trial Email me all 27 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 38 trials starting in 2026 and about 39 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 31 months from start to primary completion across 33 trials still running at the 2026-10-09 snapshot; registered median of 16 months across 408 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Arbovirus Infections trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 116
Phase 1/2 14
Phase 2 104
Phase 2/3 11
Phase 3 86
Phase 4 38
Not applicable 75
Observational 148
Expanded access 1

How many Arbovirus Infections trials are recruiting? (10)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 21
Recruiting 46
Enrolling by invitation 6
Active, not recruiting 26
Completed 390

Showing 5 of 10 statuses.

Start your 14-day trial Email me all 10 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Arbovirus Infections trials? (9)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 58
Sanofi Pasteur, a Sanofi Company 49
Valneva Austria GmbH 28
U.S. Army Medical Research and Development Command 26
Pfizer 19

Showing 5 of 9 sponsors.

Start your 14-day trial Email me all 9 sponsors as a PDF

Which drugs are being tested for Arbovirus Infections? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Yellow Fever Vaccine 22
IC51 18

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) 13
CYD Dengue Vaccine 11
TDV 6
rDEN2Δ30-7169 6
data collection 5

Showing 5 of 13 interventions.

Start your 14-day trial Email me all 13 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Arbovirus Infections trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Dengue Fever 603 7
Appendicitis 532 31
Gastroenteritis 341 32
Road Traffic Accident 262 5
Urinary Tract Infection 220 4

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Arbovirus Infections? (13)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
WhatsApp-based intervention in urban Colombia to support the prevention of arboviral diseases: a feasibility study. Pathogens and global health 2024 Yes
The use of mobile phones for the prevention and control of arboviral diseases: a scoping review. BMC public health 2021 Yes
Natural arbovirus infection rate and detectability of indoor female Aedes aegypti from Mérida, Yucatán, Mexico. PLoS neglected tropical diseases 2021 Yes
Arboviral central nervous system infections. Current opinion in infectious diseases 2021 Yes
Global risk mapping for major diseases transmitted by Aedes aegypti and Aedes albopictus. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2018 Yes

Showing 5 of 13 publications.

Start your 14-day trial Email me all 13 publications as a PDF

Sub-conditions in MeSH (10)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages